Teleflex (NYSE:TFX) Updates FY 2026 Earnings Guidance

Teleflex (NYSE:TFX) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 6.900-7.200 for the period, compared to the consensus earnings per share estimate of 6.700. The company issued revenue guidance of $2.3 billion-$2.3 billion, compared to the consensus revenue estimate of $2.3 billion.

Teleflex Trading Down 2.1%

NYSE TFX opened at $137.18 on Thursday. The company has a market cap of $6.07 billion, a P/E ratio of -6.02, a P/E/G ratio of 1.04 and a beta of 0.81. Teleflex has a 12 month low of $100.18 and a 12 month high of $144.19. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.55 and a quick ratio of 2.03. The company has a 50-day moving average of $131.41 and a 200-day moving average of $122.20.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, August 6th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.48. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The company had revenue of $570.33 million during the quarter, compared to analysts’ expectations of $559.59 million. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. As a group, equities analysts predict that Teleflex will post 6.7 earnings per share for the current year.

Teleflex Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Monday, May 25th were issued a dividend of $0.34 per share. The ex-dividend date was Friday, May 22nd. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.0%. Teleflex’s payout ratio is presently -5.96%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TFX. Zacks Research raised shares of Teleflex from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a research note on Wednesday, June 24th. Mizuho increased their target price on Teleflex from $140.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Needham & Company LLC boosted their price target on Teleflex from $147.00 to $159.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Piper Sandler upgraded Teleflex from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $140.00 to $160.00 in a report on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Teleflex has a consensus rating of “Hold” and an average target price of $148.90.

Institutional Investors Weigh In On Teleflex

Several hedge funds and other institutional investors have recently bought and sold shares of TFX. AQR Capital Management LLC increased its position in shares of Teleflex by 478.1% in the 3rd quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock worth $287,603,000 after purchasing an additional 1,956,811 shares during the last quarter. State Street Corp lifted its holdings in Teleflex by 1.5% during the 4th quarter. State Street Corp now owns 1,478,776 shares of the medical technology company’s stock worth $180,470,000 after buying an additional 22,111 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Teleflex by 0.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,250,665 shares of the medical technology company’s stock worth $152,630,000 after acquiring an additional 5,051 shares in the last quarter. Abrams Bison Investments LLC lifted its holdings in Teleflex by 5.6% in the fourth quarter. Abrams Bison Investments LLC now owns 969,000 shares of the medical technology company’s stock worth $118,257,000 after acquiring an additional 51,075 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. boosted its stake in Teleflex by 21.3% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 696,950 shares of the medical technology company’s stock valued at $85,056,000 after acquiring an additional 122,481 shares during the period. 95.62% of the stock is currently owned by hedge funds and other institutional investors.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.